Archives — May 2012 back to current month (35)

Biotech Ideas That Will Change the World: Patrick Cox (05/31/2012)

For Patrick Cox, disruptive technologies drive change and harbor opportunity. Cox, editor of Breakthrough Technology Alert and Technology Profits Confidential, and a contributor to The Daily Reckoning, strives to find novel ideas in small-cap companies that are off investors' radar screens. In this exclusive interview with The Life Sciences Report, Cox reveals—in his characteristic none-too-shy style—where he believes investors can find huge returns in biotech companies that will change the world.

more>

3 Biotech Stocks That Could Change the World (05/31/2012)

Every investor is in search of a breakthrough that will change the world. Patrick Cox has seen it all before, as an insider at Netscape Communications before it was acquired by AOL Inc. (NYSE: AOL) at the end of 1998, and before Microsoft Corp. (NASDAQ: MSFT) ever noticed that the world was shifting under its feet. The browser revolution began with the straightforward idea that all computer operating systems could be networked with seamless cross-platform ease. I recently interviewed Cox, now editor of Breakthrough Technology Alert and Technology Profits Confidential, for the story "Biotech Ideas That Will Change the World" in The Life Sciences Report. He sees a new revolution in progress as stem cell technologies and targeted therapies begin to change the entire paradigm of medical practice.

more>

House Votes to Approve FDA Funding Bill (05/30/2012)

"The House of Representatives approved a bill that helps fund the Food and Drug Administration and gives it new authority to prevent drug shortages and speed reviews of medical devices."

more>

The 152-Year-Old Brain That Changed the Course of Science (05/29/2012)

"An accident a century and a half ago has provided a major link to one of the biggest quests in all of science: getting a complete map of the human brain. Once we have that under our belts, you will see one biotech breakthrough after another after another."

more>

M&A Likely to Grow with Deal Premiums and Multiples (05/28/2012)

"The bad news for the IPO market should be good news for biopharma M&A this year. Big companies are increasingly willing to pay a big price for a larger presence, notably specialty pharma and diagnostics."

more>

'Arise and Walk!'—A Miracle Cure in the Works (05/28/2012)

"Stem cell therapies are on the threshold of making truly miraculous cures an everyday event."

more>

ASCO Abstracts 2012 (05/25/2012)

"The ASCO abstracts came out last week and a review of the massive data dump has revealed a few nuggets."

more>

Make Friends with Companion Diagnostics to Bolster Your Biotech Portfolio: Stephen Brozak (05/24/2012)

Hitting just the right target and engineering cells to perform certain tasks will unlock the deep secrets of biology and change the entire paradigm of medicine, says WBB Securities President and Managing Partner Stephen Brozak. He is not picking the ultimate winners just yet, but he is playing stem cell and personalized medicine developers as a diversified portfolio, knowing that successes will overpower the also-rans. In this exclusive interview with The Life Sciences Report, Brozak shares names from his list of finalists.

more>

It's Like Having a 'Fountain of Youth' in a Bottle (05/23/2012)

"Scientists have tweaked a benign virus so that it can extend the lifespan of mammals by up to 24%. And if taken at the right time, this modified virus could extend the average life expectancy for an American to roughly 98 years from the current 78.5."

more>

Superior Biotechnology Leads to Superior Drugs (05/23/2012)

"Revolutions in our understanding of the genome and proteome are opening up new pathways toward vanquishing the cancer foe."

more>

Collectively, 'Rare' Disease Variants Are Pretty Common (05/22/2012)

"The fact that variants are rare does not mean they are not useful for drug discovery. Cholesterol-lowering statins, for example, were identified because of rare variants that lead to extremely low cholesterol levels in their carriers."

more>

Health System Builds Telehealth Network; Sees Great Return on Investment (05/22/2012)

"Polycom, a video conference and communications company, is helping Saint Vincent Health System build a telehealth network by visually connecting healthcare professionals and patients in virtual environments across 26 facilities in Pennsylvania."

more>

Prostate-Cancer Screening Isn't Worth Risks, US Panel Says (05/22/2012)

"The 16-doctor panel urged against screening for men of all ages. The report cited the slow growth of most prostate tumors as well as false positive rates that may be as high as 80%."

more>

Prostate Cancer Screening Isn't Worth Risks, US Panel Says (05/22/2012)

"The 16-doctor panel urged against screening for men of all ages. The report cited the slow growth of most prostate tumors as well as false positive rates that may be as high as 80%."

more>

World's First Stem-Cell Drug Approved (05/21/2012)

"The decision is historic as it's both the first stem-cell drug going into formal use, as well as the first treatment for graft-versus-host disease, a devastating breakdown occurring after a bone marrow transplant that kills around 80% of children affected."

more>

Five Companies in the Casey Portfolio Worth Watching: Alex Daley (05/17/2012)

Biotech and medtech expose investors to rapid growth in healthcare innovation. In this exclusive interview with The Life Sciences Report, Chief Investment Strategist Alex Daley of Casey's Extraordinary Technology matches science to unmet needs to bring big ideas and big returns to investors.

more>

Buyout Options Gaining a Foothold (05/17/2012)

"Deals involving buyout rights have two features that make them attractive to smaller partners: up-front payments and a longer-term path to liquidity for their investors."

more>

Biotech Stock ETFs: How to Ride the Surge in Mergers & Acquisitions (05/16/2012)

"Investing in biotech stocks requires not only an understanding of the company's finances, but also knowledge of the company's potential based on its products and technologies. You can reduce some of the guesswork by using exchange-traded funds, which give you exposure without betting the farm on a single company."

more>

Stakeholders Share Data to Design Better Trials for Neurodegenerative Diseases (05/15/2012)

"The Coalition Against Major Diseases is an industrial consortia of companies willing to share precompetitive knowledge and work in support of projects identified as high priority by the FDA and in the interest of public health."

more>

FDA Panel Recommends Approval of Quad Regimen (05/14/2012)

"The FDA's Antiviral Drugs Advisory Committee agreed with the efficacy outcome, and there was little discussion or debate on the efficacy of Quad."

more>

FDA Panel Wants Higher Bar for Medical Devices Aimed at Curbing Obesity (05/14/2012)

"High-risk medical devices intended to help obese patients lose weight should result in more weight loss than lower-risk methods, an FDA advisory panel said last week."

more>

Venture Capital Is Not Dead. . .Just Resting! (05/14/2012)

"Summarizing her thoughts on the venture capital model, venture capitalist Lisa Suennen jokingly quoted Monty Python's Dead Parrot sketch: 'It is not dead. . .it is just resting!'"

more>

UMass to Break Ground on Biotech Testing Facility (05/13/2012)

"The facility allows start-up companies to conduct research, test and scale up their products, or partner with other startups. The University of Massachusetts Dartmouth says it will eliminate a common barrier for entering the life science industry."

more>

Expression Profiles Accurately Predict Breast Cancer Response to Chemotherapy (05/11/2012)

"Scientists have identified two gene-expression profiles that can predict how well breast tumors respond to specific types of chemotherapy, independent of standard variables such as age, tumor grade and estrogen receptor status."

more>

Will Mayo v. Prometheus Fire Up Pharma?: Kevin DeGeeter (05/10/2012)

Newly discovered biomarkers could provide physicians with information that will aid in the diagnosis and treatment of disease. The big question for investors is whether, in light of the recent Supreme Court ruling Mayo Collaborative Services Inc. v. Prometheus Laboratories, companies will be able to profit from that innovation. In this exclusive interview with The Life Sciences Report, Kevin DeGeeter, senior analyst with Ladenburg Thalmann & Co. Inc., shares the names of a select group of companies with good prospects, focusing on those targeting "sweet spots" in personalized medicine.

more>

Investment Banker Kevin DeGeeter's Best Idea Yet (05/10/2012)

Personalized medicine and targeted therapeutics are about narrowing down disease to achieve more definitive diagnostics and then finding more precise therapies. One could argue that every person's cancer is a different disease because the tumor cells contain the patient's own genome and are therefore different from the next individual's tumor cells. Newer genetic-based technologies are useful in detecting disease that was previously undetectable. Analyst and Director Kevin DeGeeter of New York City-based investment bank Ladenburg Thalmann & Co. Inc. follows personalized medicine and medical device companies ranging from small- to mid-cap, where investors can still reap multiples on original investment. I recently interviewed him for The Life Sciences Report and learned to look at cancer treatment in a new way.

more>

Investing in Biotech Stocks: The Latest Buyout Candidate (05/10/2012)

"The M&A possibilities—as well as deep pipelines—have triggered surging investor interest in the biotech sector."

more>

US May Speed Approval of 'Breakthrough' Drugs (05/09/2012)

"Experimental drugs that show a big effect early in development for treating serious or life-threatening diseases would get a faster and cheaper path to U.S. approval under a proposal likely to become law this year."

more>

GlaxoSmithKline Goes Hostile in Bid for Human Genome Sciences (05/09/2012)

"GlaxoSmithKline has launched a hostile bid for Human Genome Sciences, three weeks after the biotech spurned a $2.6B takeover offer."

more>

Scientists Discover New Inflammatory Target (05/09/2012)

"Scientists from Queen Mary, University of London have found a new therapeutic target to combat inflammation. The findings could lead to potential therapies for millions of people who suffer from arthritis."

more>

Taxing Jobs out of Existence: George Will on the Medical Device Tax (05/09/2012)

"In 2010 Congress, ravenous for revenue to fund Obamacare, imposed a 2.3% tax on gross revenue from U.S. sales of medical devices beginning in 2013. The tax might, however, be repealed."

more>

Researchers Tap into the Final Frontier: The Sea (05/07/2012)

"Currently, 13 therapeutic agents with marine origins are in clinical development."

more>

Catalysts Move Drug and Medtech Stocks: Michael Hay and Jocelyn August (05/03/2012)

When studying stock charts it is not hard to see sharp spikes up and deep nosedives related to development milestones and setbacks in the life cycle of a drug or medtech company. The analysts at San Diego-based Sagient Research Systems have made a science out of following the regulatory and media events that can move stocks. In this exclusive interview with The Life Sciences Report, Sagient Vice President Michael Hay and Senior Analyst Jocelyn August demonstrate their expertise with actionable ideas and provide names of companies through which investors might reap profits.

more>

Looking at Small Medtech and Biotech in Canada: Nick Waddell (05/03/2012)

Is there a developing Silicon Valley model in Canada? Not quite yet, but Publisher and Founding Editor Nick Waddell of the Vancouver-based Cantech Letter would like to see that happen. Meanwhile, he's looking for—and finding—exciting small- and micro-cap ideas as potential big returners. In this exclusive interview with The Life Sciences Report, Waddell discusses current favorite healthcare names that will surely surprise people who have not been looking North.

more>

What is the 'ASCO Effect'? (05/03/2012)

"The ASCO Effect move often starts in April. But there's almost always an additional stretch in May during which oncology stocks experience near-vertical spikes in very short periods."

more>

More Archives

2017Sep Aug Jul Jun May Apr Mar Feb Jan

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2013Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2012Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe